Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was downgraded by equities research analysts at Vetr from a “hold” rating to a “sell” rating in a research report issued on Monday. They presently have a $41.90 price target on the biopharmaceutical company’s stock. Vetr‘s target price would indicate a potential downside of 18.24% from the stock’s current price.
Other equities research analysts have also recently issued research reports about the stock. Credit Suisse Group AG set a $50.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, December 25th. Chardan Capital increased their price target on shares of Alnylam Pharmaceuticals from $73.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, November 30th. Barclays PLC reissued a “hold” rating and set a $50.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 3rd. Jefferies Group LLC set a $58.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, December 1st. Finally, Leerink Swann reissued a “market perform” rating and set a $43.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, November 10th. Eight investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $64.53.
Alnylam Pharmaceuticals (NASDAQ:ALNY) remained flat at $51.25 on Monday. 806,771 shares of the stock were exchanged. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $80.11. The company’s market capitalization is $4.41 billion. The stock’s 50-day moving average price is $50.71 and its 200 day moving average price is $47.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Wednesday, February 8th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.34) by $0.02. The business earned $17.50 million during the quarter, compared to analysts’ expectations of $10.66 million. Alnylam Pharmaceuticals had a negative net margin of 869.63% and a negative return on equity of 37.25%. The firm’s revenue for the quarter was up 130.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.07) EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals will post ($5.10) earnings per share for the current fiscal year.
In related news, Director Philip A. Sharp sold 15,000 shares of the stock in a transaction dated Wednesday, January 25th. The shares were sold at an average price of $37.95, for a total transaction of $569,250.00. Following the sale, the director now directly owns 155,795 shares of the company’s stock, valued at approximately $5,912,420.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.00% of the company’s stock.
A number of hedge funds have recently made changes to their positions in ALNY. Mn Services Vermogensbeheer B.V. increased its stake in shares of Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 87 shares during the period. Hall Laurie J Trustee purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at approximately $160,000. Neuberger Berman Group LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $205,000. Notis McConarty Edward purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $229,000. Finally, Fayerweather Charles increased its stake in shares of Alnylam Pharmaceuticals by 3.5% in the second quarter. Fayerweather Charles now owns 4,165 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 140 shares during the period. 88.70% of the stock is currently owned by institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
To view Vetr’s full report, visit Vetr’s official website.